• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Mersana Therapeutics Inc. (Amendment)

    2/14/24 6:55:52 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRSN alert in real time by email
    SC 13G/A 1 ss3005734_sc13ga.htm AMENDMENT NO. 1
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Mersana Therapeutics, Inc.
    (Name of Issuer)

     

     

    Common Stock, $0.0001 par value per share
    (Title of Class of Securities)

     

     

    59045L106
    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
       

     

     

    CUSIP No. 59045L106  SCHEDULE 13G Page 2 of 7 Pages

     

             
    1

    NAME OF REPORTING PERSONS

    OrbiMed Capital LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

    12

    TYPE OF REPORTING PERSON

    IA

     

     

     

       

     

     

     

    CUSIP No. 59045L106  SCHEDULE 13G Page 3 of 7 Pages

     

             
    1

    NAME OF REPORTING PERSONS

    OrbiMed Advisors LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

    12

    TYPE OF REPORTING PERSON

    IA

     

     

     

     

     

       

     

     

    CUSIP No.  59045L106  SCHEDULE 13G Page 4 of 7 Pages

     

    Item 1.   (a) Name of Issuer:

    Mersana Therapeutics, Inc.

        (b) Address of Issuer’s Principal Executive Offices:

    840 Memorial Drive

    Cambridge, Massachusetts 02139

    Item 2.   (a) Name of Person Filing:

    OrbiMed Capital LLC

    OrbiMed Advisors LLC

        (b) Address of Principal Business Office:

    601 Lexington Avenue, 54th Floor

    New York, NY 10022

        (c) Citizenship:

    Please refer to Item 4 on each cover page for each Reporting Person.

        (d) Title of Class of Securities:

    Common Stock, $0.0001 par value per share

        (e) CUSIP No.:

    59045L106 

     

     

     

     

     

     

     

     

     

     

       

     

     

    CUSIP No. 59045L106  SCHEDULE 13G Page 5 of 7 Pages

     

     

    Item 3.      

    OrbiMed Advisors LLC and OrbiMed Capital LLC are investment advisors in accordance with ss.240.13d-1(b)(1)(ii)(E).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

       

     

     

     

    CUSIP No. 59045L106  SCHEDULE 13G Page 6 of 7 Pages

     

     

    Item 4. Ownership:

    Information with respect to the Reporting Person’s ownership as of December 31, 2023 is incorporated by reference to items (5) - (9) and (11) of the cover page for the Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.

    Item 9. Notice of Dissolution of Group.

    Not Applicable.

    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

     

     

     

       

     

     

     

    CUSIP No. 59045L106  SCHEDULE 13G Page 7 of 7 Pages

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

           
      OrbiMed Advisors LLC
           
      By: /s/ Carl L. Gordon
        Name:  Carl L. Gordon
        Title:  Member

     

           
      OrbiMed Capital LLC
           
      By: /s/ Carl L. Gordon
        Name:  Carl L. Gordon
        Title:  Member

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $MRSN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MRSN

    DatePrice TargetRatingAnalyst
    2/6/2025Outperform
    William Blair
    11/15/2024$5.00Buy
    Citigroup
    3/19/2024$5.00Underweight → Neutral
    JP Morgan
    2/29/2024$6.00Neutral → Buy
    BTIG Research
    2/29/2024$7.00Neutral → Buy
    Guggenheim
    2/29/2024$2.00 → $7.00Neutral → Outperform
    Wedbush
    12/4/2023$1.00 → $5.00Neutral → Buy
    Citigroup
    7/28/2023$7.00 → $1.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $MRSN
    SEC Filings

    See more
    • Mersana Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

      8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)

      7/3/25 4:10:34 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)

      6/13/25 4:22:01 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)

      6/2/25 8:23:21 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Alleva Lawrence M

      4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

      6/13/25 5:15:12 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hack Andrew A. F.

      4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

      6/13/25 5:10:40 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Dere Willard H

      4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

      6/13/25 5:02:42 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Mersana Therapeutics

      William Blair initiated coverage of Mersana Therapeutics with a rating of Outperform

      2/6/25 7:08:59 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup resumed coverage on Mersana Therapeutics with a new price target

      Citigroup resumed coverage of Mersana Therapeutics with a rating of Buy and set a new price target of $5.00

      11/15/24 8:15:56 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics upgraded by JP Morgan with a new price target

      JP Morgan upgraded Mersana Therapeutics from Underweight to Neutral and set a new price target of $5.00

      3/19/24 7:51:31 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

      31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior lines of therapy CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced additional interim Phase 1 clinical data for emiltatug ledadotin (Emi-Le; XMT-1660), the company's B7-H4-directed Dolasynthen ADC. These data are being presented in an oral session today at the American Socie

      6/2/25 8:10:31 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics to Present at Upcoming Investor Conferences

      CAMBRIDGE, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in the following upcoming investor events: TD Cowen 6th Annual Oncology Innovation SummitFormat:         Fireside chatDate/Time:   Tuesday, May 27, 2025, at 2:00 p.m. Eastern TimeGoldman Sachs 46th Annual Global Healthcare Conference Format:        PresentationDate/Time:  Monday, June 9, 2025, at 2:00 p.m. Eastern Time Live webcasts of these events will be available on the I

      5/20/25 8:00:59 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

      In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ:MRSN), please note that there was a transcription error in the last cell of the first table. The Median OS should have been 5.7 months rather than 1.7 months. The corrected release follows: Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate dosesEncouraging preliminary time-to-event data in triple-negative breast cancer (

      5/15/25 9:20:09 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Mersana Therapeutics Inc.

      SC 13D/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

      11/15/24 4:45:57 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

      SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

      11/14/24 5:45:55 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

      SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

      11/14/24 6:01:51 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Leadership Updates

    Live Leadership Updates

    See more
    • Mersana Therapeutics Announces Changes in Leadership

      Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named President and CEOBrian DeSchuytner named Chief Operating Officer; Mohan Bala, Ph.D., named Chief Development Officer CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the retirement of Anna Protopapas, President and CEO, effective September 10, 2023, and the

      9/6/23 7:00:40 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Provides Statement About SVB

      CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided an update about its capital resources. A de minimis amount of Mersana's capital is currently held in a checking account at Silicon Valley Bank (SVB). The balance of the company's capital resources is held in a custodial account managed by another institution and in money market funds of institutions other than SVB. Mersana has a loan and security agreement with Oxford Finance LLC and SVB. As previously

      3/10/23 7:10:38 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Announces Appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership

      CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership, effective Monday, October 25, 2021. Dr. Bala will assume strategic product planning responsibilities from Brian DeSchuytner who has been named SVP and Chief Financial Officer. Mr. DeSchuytner will continue to lead finance, business development, corporate strategy and investor relations and remain Mersana's pri

      10/25/21 8:00:00 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Financials

    Live finance-specific insights

    See more
    • CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

      In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ:MRSN), please note that there was a transcription error in the last cell of the first table. The Median OS should have been 5.7 months rather than 1.7 months. The corrected release follows: Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate dosesEncouraging preliminary time-to-event data in triple-negative breast cancer (

      5/15/25 9:20:09 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

      Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate dosesEncouraging preliminary time-to-event data in triple-negative breast cancer (TNBC) Second, higher dose recently selected for expansion in post-topoisomerase-1 inhibitor ADC (post-topo-1) TNBC; patient enrollment advancing in both dose expansion cohorts Plan to report initial clinical data from expansion in second half of 2025Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a

      5/15/25 7:00:40 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

      Cost-saving initiatives expected to extend company's cash runway and support current operating plan commitments into mid-2026 Company to host conference call at 8:00 a.m. ET on May 15 to discuss business updates and first quarter 2025 financial results CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the implementation of a strategic restructuring and reprioritization plan aimed at extending the company's cash runway and furthering the development of emiltatug ledad

      5/6/25 7:00:51 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care